Cyclization and Cyclic Peptides

Cyclization closes a peptide into a ring by forming a covalent bond the linear sequence lacks. The routes differ in chemistry and reversibility: head-to-tail joins the N-terminus to the C-terminus through an ordinary amide, side-chain lactam bridges link a lysine to an aspartate or glutamate, disulfides oxidise two cysteines, and thioether or hydrocarbon linkages are used where a non-reducible bond is wanted. All reduce conformational freedom, so less entropy is lost on binding.

Several long-established drugs are cyclic. Oxytocin and vasopressin each close a six-residue ring with a disulfide, somatostatin and octreotide do likewise, cyclosporine is an eleven-residue head-to-tail macrocycle, and the polymyxins and vancomycin are cyclic antibacterials. A head-to-tail cycle has no free termini at all, removing exopeptidase attack entirely rather than slowing it, which is part of why such molecules survive conditions that destroy linear peptides in minutes.

Cyclization is therefore chosen when preorganisation and protease resistance are both wanted, at the cost of harder synthesis, since ring closure competes with polymerisation and runs at high dilution in often low yield. A second, more speculative benefit is membrane permeability: cyclosporine is orally bioavailable because its macrocycle plus extensive backbone N-methylation lets it shield its own polar amides and present a lipophilic exterior.

That example is regularly over-generalised. Cyclosporine is an outlier rather than a template, most cyclic peptides remain poorly absorbed by mouth, and a claim that cyclisation confers oral activity is a hypothesis needing its own pharmacokinetic data. A related error treats a disulfide ring as equivalent to a lactam: disulfides are reduced by intracellular glutathione and can scramble, while amide and hydrocarbon bridges cannot.